Pfizer, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Chris Schott from J.P. Morgan maintained a Hold rating on the stock and has a $30.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Chris Schott has given his Hold rating due to a combination of factors impacting Pfizer’s financial outlook. The company’s third-quarter sales projections are slightly below market expectations, primarily due to lower-than-anticipated revenues from Paxlovid and Comirnaty. Despite these challenges, Pfizer’s core business remains robust, with growth in key products like Ibrance, Eliquis, and Xtandi, which offsets some of the declines in other areas.
Looking forward, Schott notes that Pfizer’s stock appears undervalued, trading at a relatively low earnings multiple. However, the potential for future growth hinges on the successful development of its pipeline, particularly in oncology and the newly acquired Metsera obesity program. With significant data expected only in the latter half of 2026 or beyond, Schott believes that more progress is necessary to alter investor sentiment significantly, justifying the Hold rating.
Schott covers the Healthcare sector, focusing on stocks such as Pfizer, Eli Lilly & Co, and Merck & Company. According to TipRanks, Schott has an average return of 2.0% and a 53.13% success rate on recommended stocks.
In another report released on October 1, TD Cowen also reiterated a Hold rating on the stock with a $30.00 price target.